NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
1.090
+0.070 (6.86%)
Nov 28, 2025, 1:00 PM EST - Market closed
NovaBay Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 10.27 | 9.75 | 10.46 | 14.37 | 10.18 | 9.92 | Upgrade |
Other Revenue | 0.03 | 0.03 | - | 0.03 | 0.02 | 0.02 | Upgrade |
| 10.3 | 9.78 | 10.46 | 14.4 | 10.2 | 9.93 | Upgrade | |
Revenue Growth (YoY) | 390.34% | -6.45% | -27.42% | 41.16% | 2.72% | 50.54% | Upgrade |
Cost of Revenue | 3.78 | 3.3 | 4.37 | 6.62 | 3.69 | 3.97 | Upgrade |
Gross Profit | 6.52 | 6.48 | 6.08 | 7.78 | 6.52 | 5.96 | Upgrade |
Selling, General & Admin | 11.61 | 11.41 | 10.15 | 15.29 | 15.33 | 12.11 | Upgrade |
Research & Development | 0.04 | 0.04 | 0.03 | 0.17 | 0.04 | 0.29 | Upgrade |
Operating Expenses | 11.65 | 11.46 | 10.19 | 15.46 | 15.38 | 12.39 | Upgrade |
Operating Income | -5.12 | -4.97 | -4.1 | -7.68 | -8.86 | -6.43 | Upgrade |
Interest Expense | -0.03 | -0.9 | -1.69 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | -0.29 | -0.44 | -0.39 | 3.25 | 3.04 | -5.51 | Upgrade |
EBT Excluding Unusual Items | -5.44 | -6.31 | -6.19 | -4.43 | -5.82 | -11.93 | Upgrade |
Impairment of Goodwill | - | - | - | -4.18 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -0.87 | -0.87 | - | - | - | - | Upgrade |
Asset Writedown | -0.68 | - | - | -2.56 | - | - | Upgrade |
Other Unusual Items | - | -0.03 | 0.04 | 0.56 | - | 0.9 | Upgrade |
Pretax Income | -6.99 | -7.21 | -6.15 | -10.61 | -5.82 | -11.03 | Upgrade |
Income Tax Expense | - | - | - | - | - | 0.01 | Upgrade |
Earnings From Continuing Operations | -6.99 | -7.21 | -6.15 | -10.61 | -5.82 | -11.04 | Upgrade |
Earnings From Discontinued Operations | 10.23 | -0.01 | -3.5 | - | - | - | Upgrade |
Net Income | 3.24 | -7.22 | -9.64 | -10.61 | -5.82 | -11.04 | Upgrade |
Preferred Dividends & Other Adjustments | - | 1.39 | 7.06 | 5.66 | 0.74 | - | Upgrade |
Net Income to Common | 3.24 | -8.61 | -16.7 | -16.27 | -6.56 | -11.04 | Upgrade |
Shares Outstanding (Basic) | 7 | 3 | 0 | 0 | 0 | 0 | Upgrade |
Shares Outstanding (Diluted) | 7 | 3 | 0 | 0 | 0 | 0 | Upgrade |
Shares Change (YoY) | 831.36% | 2730.00% | 160.87% | 29.11% | 24.43% | 62.08% | Upgrade |
EPS (Basic) | 0.47 | -2.53 | -139.14 | -353.59 | -184.09 | -385.53 | Upgrade |
EPS (Diluted) | 0.47 | -2.53 | -139.14 | -353.59 | -184.09 | -385.53 | Upgrade |
Free Cash Flow | 2.95 | -5.4 | -4.65 | -6.77 | -9.24 | -4.75 | Upgrade |
Free Cash Flow Per Share | 0.42 | -1.59 | -38.77 | -147.09 | -259.45 | -165.79 | Upgrade |
Gross Margin | 63.32% | 66.26% | 58.19% | 54.02% | 63.85% | 60.04% | Upgrade |
Operating Margin | -49.74% | -50.85% | -39.23% | -53.32% | -86.85% | -64.69% | Upgrade |
Profit Margin | 31.48% | -88.01% | -159.70% | -112.92% | -64.28% | -111.12% | Upgrade |
Free Cash Flow Margin | 28.66% | -55.16% | -44.51% | -46.97% | -90.59% | -47.78% | Upgrade |
EBITDA | -5.1 | -4.93 | -4.05 | -7.2 | -8.74 | -6.38 | Upgrade |
EBITDA Margin | -49.53% | -50.44% | -38.75% | -49.96% | -85.68% | -64.17% | Upgrade |
D&A For EBITDA | 0.02 | 0.04 | 0.05 | 0.48 | 0.12 | 0.05 | Upgrade |
EBIT | -5.12 | -4.97 | -4.1 | -7.68 | -8.86 | -6.43 | Upgrade |
EBIT Margin | -49.74% | -50.85% | -39.23% | -53.32% | -86.85% | -64.69% | Upgrade |
Revenue as Reported | 9.78 | 9.78 | 10.46 | 14.4 | 10.2 | 9.93 | Upgrade |
Advertising Expenses | - | 0.7 | 1.1 | 2 | 3.2 | 1.7 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.